Transcriptomic changes in signaling using NCI-H358 cells treated with a KRAS G12C or a SOS1::KRASi inhibitor
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 24 samples: 12 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung AdenocarcinomaCancer research · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE275534_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1151634 and SRA study SRP528300. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 12 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8479075 H358_NT_6h_1_rep1 H358_NT_6h_1
- GSM8479076 H358_NT_6h_1_rep2 H358_NT_6h_1
- GSM8479077 H358_NT_6h_2_rep1 H358_NT_6h_2
- GSM8479078 H358_NT_6h_2_rep2 H358_NT_6h_2
- GSM8479079 H358_NT_BI3406_6h_1_rep1 H358_NT_BI3406_6h_1
- GSM8479080 H358_NT_BI3406_6h_1_rep2 H358_NT_BI3406_6h_1
- GSM8479081 H358_NT_BI3406_6h_2_rep1 H358_NT_BI3406_6h_2
- GSM8479082 H358_NT_BI3406_6h_2_rep2 H358_NT_BI3406_6h_2
- GSM8479083 H358_NT_MRTX849_6h_1_rep1 H358_NT_MRTX849_6h_1
- GSM8479084 H358_NT_MRTX849_6h_1_rep2 H358_NT_MRTX849_6h_1
- GSM8479085 H358_NT_MRTX849_6h_2_rep1 H358_NT_MRTX849_6h_2
- GSM8479086 H358_NT_MRTX849_6h_2_rep2 H358_NT_MRTX849_6h_2
- GSM8479087 H358_NT_MRTX849_72h_1_rep1 H358_NT_MRTX849_72h_1
- GSM8479088 H358_NT_MRTX849_72h_1_rep2 H358_NT_MRTX849_72h_1
- GSM8479089 H358_NT_MRTX849_72h_2_rep1 H358_NT_MRTX849_72h_2
- GSM8479090 H358_NT_MRTX849_72h_2_rep2 H358_NT_MRTX849_72h_2
- GSM8479091 H358_NT_MRTX849_BI3406_6h_1_rep1 H358_NT_MRTX849_BI3406_…
- GSM8479092 H358_NT_MRTX849_BI3406_6h_1_rep2 H358_NT_MRTX849_BI3406_…
- GSM8479093 H358_NT_MRTX849_BI3406_6h_2_rep1 H358_NT_MRTX849_BI3406_…
- GSM8479094 H358_NT_MRTX849_BI3406_6h_2_rep2 H358_NT_MRTX849_BI3406_…
- GSM8479095 H358_NT_MRTX849_BI3406_72h_1_rep1 H358_NT_MRTX849_BI3406_…
- GSM8479096 H358_NT_MRTX849_BI3406_72h_1_rep2 H358_NT_MRTX849_BI3406_…
- GSM8479097 H358_NT_MRTX849_BI3406_72h_2_rep1 H358_NT_MRTX849_BI3406_…
- GSM8479098 H358_NT_MRTX849_BI3406_72h_2_rep2 H358_NT_MRTX849_BI3406_…
- GSE253447 Transcriptomic changes in a KRASG12C mutant cell line (H358 cells) treated with the allosteric SHP2 inhibitor TNO155 for different times 18 samples shares kras, g12c, inhibitor, changes, treated
- GSE225061 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response 217 samples shares kras, g12c, sos1, inhibitor
- GSE250032 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (Quant-Seq 2) 65 samples shares kras, g12c, sos1, inhibitor
- GSE225060 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (RNA-Seq). 33 samples shares kras, g12c, sos1, inhibitor
- GSE255847 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response [Tru-seq] 22 samples shares kras, g12c, sos1, inhibitor
- GSE315129 ChIP-seq analysis of H3K27ac changes in pancreatic cancer cells treated with EZH2 and KRAS inhibitors 8 samples shares kras, inhibitor, changes, treated
- GSE278656 Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C 20 samples shares kras, g12c, inhibitor
- GSE315052 NSCLC KRAS G12C MUTANT CELLS ARE DEPENDENT ON MUC1-C FOR RESISTANCE TO KRAS INHIBITORS 6 samples shares kras, g12c, inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.